. Bibliographie-1, M. Carpelan-holmström, S. Nordling, E. Pukkala, R. Sankila et al., Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry, Gut, vol.54, issue.3, pp.385-392, 2005.

T. Cartwright, D. Richards, and K. Boehm, Cancer of the Pancreas: Are we Making Progress? A Review of Studies in the US Oncology Research Network, Cancer Control, vol.25, issue.18, pp.308-321, 2008.
DOI : 10.1200/JCO.2005.01.9661

R. Siegel, K. Miller, and A. Jemal, Cancer statistics, 2015. CA Cancer J Clin, pp.5-29, 2015.

A. Doussot, O. Reilly, E. Lowery, M. Goodman, K. Do et al., Available from: https://www.pancan.org/wp-content/uploads FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma, Pancreatic Cancer Action Network. Pancreatic Cancer Facts 2016, pp.3512-3533, 2015.

S. Gillen, T. Schuster, M. Z. Büschenfelde, C. Friess, H. Kleeff et al., Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages, PLoS Medicine, vol.23, issue.4, p.1000267, 2010.
DOI : 10.1371/journal.pmed.1000267.s005

J. Ferlay, E. Steliarova-foucher, J. Lortet-tieulent, S. Rosso, J. Coebergh et al., Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012, European Journal of Cancer, vol.49, issue.6, pp.1374-403, 2013.
DOI : 10.1016/j.ejca.2012.12.027

D. Yadav and A. Lowenfels, The Epidemiology of Pancreatitis and Pancreatic Cancer, Gastroenterology, vol.144, issue.6, pp.1252-61, 2013.
DOI : 10.1053/j.gastro.2013.01.068

S. Iodice, S. Gandini, P. Maisonneuve, and A. Lowenfels, Tobacco and the risk of pancreatic cancer: a review and meta-analysis. Langenbecks Arch Surg, pp.535-580, 2008.

D. Li, J. Morris, J. Liu, M. Hassan, R. Day et al., Body Mass Index and Risk, Age of Onset, and Survival in Patients With Pancreatic Cancer, JAMA, vol.301, issue.24, pp.2553-62, 2009.
DOI : 10.1001/jama.2009.886

V. Durlach, Cancer et diabète de type II [Internet] Available from, 2017.

R. Huxley, A. Ansary-moghaddam, A. Berrington-de-gonzález, F. Barzi, and M. Woodward, Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies, British Journal of Cancer, vol.95, issue.11, pp.2076-83, 2005.
DOI : 10.1093/jnci/djg105

J. Windsor, An update on familial pancreatic cancer and the management of asymptomatic relatives, HPB, vol.9, issue.1, pp.4-7, 2007.
DOI : 10.1080/13651820600985325

S. Raimondi, A. Lowenfels, A. Morselli-labate, P. Maisonneuve, and R. Pezzilli, Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection, Best Practice & Research Clinical Gastroenterology, vol.24, issue.3, pp.349-58, 2010.
DOI : 10.1016/j.bpg.2010.02.007

C. St, L. Cl, R. Kg, R. J. De-andrade-m, and P. Gm, Probability of Pancreatic Cancer Following Diabetes: A Population-Based Study, Gastroenterology, 2005.

M. Zins, E. Petit, I. Boulay-coletta, A. Balaton, O. Marty et al., Imagerie de l'adénocarcinome du pancréas. Datarevues0221036300866-C2759 [Internet], 2008.

J. Campbell and S. Wilson, Pancreatic neoplasms: how useful is evaluation with US? Radiology, pp.341-345, 1988.

G. Fuhrman, C. Charnsangavej, J. Abbruzzese, K. Cleary, R. Martin et al., Thin-section contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms, The American Journal of Surgery, vol.167, issue.1, pp.104-115, 1994.
DOI : 10.1016/0002-9610(94)90060-4

P. Carcinoma, The Role of High-Resolution Multislice Spiral CT in the Diagnosis and Assessment of Resectability Available from: https, Internet]. PubMed Journals, 12541123.

G. Boland, O. Malley, M. Saez, M. Fernandez-del-castillo, C. Warshaw et al., Pancreatic-phase versus portal vein-phase helical CT of the pancreas: optimal temporal window for evaluation of pancreatic adenocarcinoma., American Journal of Roentgenology, vol.172, issue.3, pp.605-613, 1999.
DOI : 10.2214/ajr.172.3.10063844

N. Mcnulty, I. Francis, J. Platt, R. Cohan, M. Korobkin et al., Multi???Detector Row Helical CT of the Pancreas: Effect of Contrast-enhanced Multiphasic Imaging on Enhancement of the Pancreas, Peripancreatic Vasculature, and Pancreatic Adenocarcinoma, Radiology, vol.220, issue.1, 2001.
DOI : 10.1148/radiology.220.1.r01jl1897

O. Graf, G. Boland, A. Warshaw, C. Fernandez-del-castillo, P. Hahn et al., Arterial versus portal venous helical CT for revealing pancreatic adenocarcinoma: conspicuity of tumor and critical vascular anatomy., American Journal of Roentgenology, vol.169, issue.1
DOI : 10.2214/ajr.169.1.9207510

J. Fletcher, M. Wiersema, M. Farrell, J. Fidler, L. Burgart et al., Pancreatic Malignancy: Value of Arterial, Pancreatic, and Hepatic Phase Imaging with Multi???Detector Row CT, Radiology, vol.229, issue.1, pp.81-90, 2003.
DOI : 10.1148/radiol.2291020582

D. Lu, S. Vedantham, R. Krasny, B. Kadell, W. Berger et al., Two-phase helical CT for pancreatic tumors: pancreatic versus hepatic phase enhancement of tumor, pancreas, and vascular structures., Radiology, vol.199, issue.3, pp.697-701, 1996.
DOI : 10.1148/radiology.199.3.8637990

P. Legmann, O. Vignaux, B. Dousset, A. Baraza, L. Palazzo et al., Pancreatic tumors: comparison of dual-phase helical CT and endoscopic sonography., American Journal of Roentgenology, vol.170, issue.5, 1998.
DOI : 10.2214/ajr.170.5.9574609

D. Bluemke, J. Cameron, R. Hruban, H. Pitt, S. Siegelman et al., Potentially resectable pancreatic adenocarcinoma: spiral CT assessment with surgical and pathologic correlation., Radiology, vol.197, issue.2, pp.381-386, 1995.
DOI : 10.1148/radiology.197.2.7480681

A. Vellet, W. Romano, D. Bach, R. Passi, D. Taves et al., Adenocarcinoma of the pancreatic ducts: comparative evaluation with CT and MR imaging at 1.5 T., Radiology, vol.183, issue.1, 1992.
DOI : 10.1148/radiology.183.1.1312736

O. Serrano, M. Chaudhry, and S. Leach, The Role of PET Scanning in Pancreatic Cancer, Advances in Surgery, vol.44, issue.1, pp.313-338, 2010.
DOI : 10.1016/j.yasu.2010.05.007

J. Pietryga and D. Morgan, Imaging preoperatively for pancreatic adenocarcinoma, J Gastrointest Oncol Mar, vol.276, issue.4, pp.343-57, 2015.

J. Neoptolemos, D. Stocken, J. Dunn, J. Almond, H. Beger et al., Influence of Resection Margins on Survival for Patients With Pancreatic Cancer Treated by Adjuvant Chemoradiation and/or Chemotherapy in the ESPAC-1 Randomized Controlled Trial, Annals of Surgery, vol.234, issue.6, pp.758-68, 2001.
DOI : 10.1097/00000658-200112000-00007

K. Bilimoria, M. Talamonti, S. Sener, M. Bilimoria, A. Stewart et al., Effect of Hospital Volume on Margin Status after Pancreaticoduodenectomy for Cancer, Journal of the American College of Surgeons, vol.207, issue.4, pp.510-519, 2008.
DOI : 10.1016/j.jamcollsurg.2008.04.033

J. Tol, D. Gouma, C. Bassi, C. Dervenis, M. Montorsi et al., Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: A consensus statement by the International Study Group on Pancreatic Surgery (ISGPS), Surgery, vol.156, issue.3, pp.591-600, 2014.
DOI : 10.1016/j.surg.2014.06.016

J. Delpeiro, F. Paye, P. Bachellier, and J. Boyer, Cancer du pancréas [Internet]. 112AD, 2017.

F. Campbell, . Cairns, R. Duthie, and . Feakins, Dataset for the histopathological reporting of carcinomas of the pancreas, ampulla of vater and common bile duct. Royal College of Pathologist, 2017.

D. Chang, A. Johns, N. Merrett, A. Gill, E. Colvin et al., Margin Clearance and Outcome in Resected Pancreatic Cancer, Journal of Clinical Oncology, vol.27, issue.17, pp.2855-62, 2009.
DOI : 10.1200/JCO.2008.20.5104

J. Delpero, P. Bachellier, N. Regenet, L. Treut, Y. Paye et al., Pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a French multicentre prospective evaluation of resection margins in 150 evaluable specimens, HPB, vol.16, issue.1, 2014.
DOI : 10.1111/hpb.12061

A. Schlitter and I. Esposito, Definition of Microscopic Tumor Clearance (R0) in Pancreatic Cancer Resections, Cancers, vol.238, issue.4, pp.2001-2011, 2010.
DOI : 10.1016/j.gassur.2006.08.018

S. Gourgou-bourgade, C. Bascoul-mollevi, F. Desseigne, M. Ychou, O. Bouché et al., Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial, Journal of Clinical Oncology, vol.31, issue.1, pp.23-32, 2013.
DOI : 10.1200/JCO.2012.44.4869

T. Conroy, F. Desseigne, M. Ychou, O. Bouché, R. Guimbaud et al., FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer, New England Journal of Medicine, vol.364, issue.19, pp.1817-1842, 2011.
DOI : 10.1056/NEJMoa1011923

URL : https://hal.archives-ouvertes.fr/hal-00598658

D. Stocken, M. Büchler, C. Dervenis, C. Bassi, H. Jeekel et al., Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer, British Journal of Cancer, vol.341, issue.8, pp.1372-81, 2005.
DOI : 10.1002/cncr.10831

J. Neoptolemos, D. Stocken, H. Friess, C. Bassi, J. Dunn et al., A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer, New England Journal of Medicine, vol.350, issue.12, pp.1200-1210, 2004.
DOI : 10.1056/NEJMoa032295

H. Oettle, P. Neuhaus, A. Hochhaus, J. Hartmann, K. Gellert et al., Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer, JAMA, vol.310, issue.14, pp.1473-81, 2009.
DOI : 10.1001/jama.2013.279201

J. Neoptolemos, D. Stocken, C. Bassi, P. Ghaneh, D. Cunningham et al., Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection, JAMA, vol.304, issue.10, pp.1073-81, 2010.
DOI : 10.1001/jama.2010.1275

V. Hoff, D. Ervin, T. Arena, F. Chiorean, E. Infante et al., Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine, New England Journal of Medicine, vol.369, issue.18, pp.1691-703, 2013.
DOI : 10.1056/NEJMoa1304369

N. Chiang, J. Chang, Y. Shan, and L. Chen, Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer, Expert Opinion on Pharmacotherapy, vol.33, issue.10, pp.1413-1433
DOI : 10.1016/S0140-6736(15)01035-1

R. Kelley and A. Ko, Erlotinib in the treatment of advanced pancreatic cancer, Biol Targets Ther, vol.2, issue.1, pp.83-95, 2008.

P. Bailey, D. Chang, K. Nones, A. Johns, A. Patch et al., Genomic analyses identify molecular subtypes of pancreatic cancer, Nature, vol.4, issue.7592, pp.47-52, 2016.
DOI : 10.1038/ncomms3612

S. Cunha, A. Rault, A. Laurent, C. Adhoute, X. Vendrely et al., Surgical Resection after Radiochemotherapy in Patients with Unresectable Adenocarcinoma of the Pancreas, Journal of the American College of Surgeons, vol.201, issue.3, pp.359-65, 2005.
DOI : 10.1016/j.jamcollsurg.2005.04.008

X. Adhoute, D. Smith, V. Vendrely, A. Rault, S. Cunha et al., Subsequent resection of locally advanced pancreatic carcinoma after chemoradiotherapy, Gastroent??rologie Clinique et Biologique, vol.30, issue.2, 2006.
DOI : 10.1016/S0399-8320(06)73157-8

Q. Denost, C. Laurent, J. Adam, M. Capdepont, V. Vendrely et al., Pancreaticoduodenectomy following chemoradiotherapy for locally advanced adenocarcinoma of the pancreatic head, HPB, vol.15, issue.9, pp.716-739, 2013.
DOI : 10.1111/hpb.12039

K. Christians, S. Tsai, A. Mahmoud, R. P. Thomas, J. Wiebe et al., Neoadjuvant FOLFIRINOX for Borderline Resectable Pancreas Cancer: A New Treatment Paradigm?, The Oncologist, vol.19, issue.3, pp.266-74, 2014.
DOI : 10.1634/theoncologist.2013-0273

L. Barbier, O. Turrini, E. Grégoire, F. Viret, L. Treut et al., Pancreatic head resectable adenocarcinoma: preoperative chemoradiation improves local control but does not affect survival, HPB, vol.13, issue.1, pp.64-73, 2011.
DOI : 10.1111/j.1477-2574.2010.00245.x

H. Zhan, J. Xu, D. Wu, Z. Wu, L. Wang et al., Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of prospective studies, Cancer Medicine, vol.20, issue.Suppl 3, 2017.
DOI : 10.3748/wjg.v20.i31.10740

Y. Kwak, J. Lee, M. Lee, H. Chun, D. Kim et al., Definitive concurrent chemoradiotherapy in locally advanced pancreatic cancer, Radiation Oncology Journal, vol.32, issue.2, pp.49-56
DOI : 10.3857/roj.2014.32.2.49

P. Hammel, F. Huguet, J. Van-laethem, D. Goldstein, B. Glimelius et al., Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib, JAMA, vol.315, issue.17, pp.1844-53, 2016.
DOI : 10.1001/jama.2016.4324

V. Verma, J. Li, and C. Lin, Neoadjuvant Therapy for Pancreatic Cancer, American Journal of Clinical Oncology, vol.39, issue.3, pp.302-315
DOI : 10.1097/COC.0000000000000278

N. Girard, F. Mornex, C. Partensky, and J. Delpero, Int??r??t de la chimio-radioth??rapie n??o-adjuvante dans le cancer pancr??atique, Gastroent??rologie Clinique et Biologique, vol.30, issue.12, 1375.
DOI : 10.1016/S0399-8320(06)73558-8

J. Hoffman, H. Cooper, N. Young, and T. Pendurthi, Preoperative chemotherapy of chemoradiotherapy for the treatment of adenocarcinoma of the pancreas and ampulla of Vater, Journal of Hepato-Biliary-Pancreatic Surgery, vol.5, issue.3, pp.251-255, 1998.
DOI : 10.1007/s005340050042

F. Huguet, F. Mornex, and A. Orthuon, Radiothérapie des cancers du pancréas. Cancer/Radiothérapie, pp.169-73, 2016.

F. Huguet, K. Goodman, D. Azria, S. Racadot, and R. Abrams, Radiotherapy Technical Considerations in the Management of Locally Advanced Pancreatic Cancer: American-French Consensus Recommendations, International Journal of Radiation Oncology*Biology*Physics, vol.83, issue.5, pp.1355-64, 2012.
DOI : 10.1016/j.ijrobp.2011.11.050

D. Goldstein, V. Hazel, G. Walpole, E. Underhill, C. Kotasek et al., Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer, British Journal of Cancer, vol.6, issue.4, pp.464-71, 2007.
DOI : 10.1200/JCO.2005.23.911

J. Murphy, S. Adusumilli, K. Griffith, M. Ray, M. Zalupski et al., Full-Dose Gemcitabine and Concurrent Radiotherapy for Unresectable Pancreatic Cancer, International Journal of Radiation Oncology*Biology*Physics, vol.68, issue.3, pp.801-809, 2007.
DOI : 10.1016/j.ijrobp.2006.12.053

C. Moertel, S. Frytak, R. Hahn, O. Connell, M. Reitemeier et al., Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil. The gastrointestinal tumor study group, Cancer, vol.47, issue.8, pp.1705-1715, 1981.
DOI : 10.1002/1097-0142(19811015)48:8<1705::AID-CNCR2820480803>3.0.CO;2-4

F. Huguet, N. Girard, C. Guerche, C. Hennequin, F. Mornex et al., Chemoradiotherapy in the Management of Locally Advanced Pancreatic Carcinoma: A Qualitative Systematic Review, Journal of Clinical Oncology, vol.27, issue.13, pp.2269-77, 2009.
DOI : 10.1200/JCO.2008.19.7921

M. Milano, S. Chmura, M. Garofalo, C. Rash, J. Roeske et al., Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome, International Journal of Radiation Oncology*Biology*Physics, vol.59, issue.2, pp.445-53, 2004.
DOI : 10.1016/j.ijrobp.2003.11.003

J. Landry, N. Esiashvili, J. Ting, and C. Staley, Intensity modulated radiation therapy employing the volume at risk approach to minimize small bowel and renal toxicity when treating patients with locally advanced pancreatic carcinomas, International Journal of Radiation Oncology*Biology*Physics, vol.51, issue.3, p.270, 2001.
DOI : 10.1016/S0360-3016(01)02319-7

S. Mukherjee, C. Hurt, J. Bridgewater, S. Falk, S. Cummins et al., Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial, The Lancet Oncology, vol.14, issue.4, pp.317-343
DOI : 10.1016/S1470-2045(13)70021-4

F. Huguet, S. Mukherjee, and M. Javle, Locally Advanced Pancreatic Cancer: The Role of Definitive Chemoradiotherapy, Clinical Oncology, vol.26, issue.9, pp.560-568, 2014.
DOI : 10.1016/j.clon.2014.06.002

B. Ganeshan and K. Miles, Quantifying tumour heterogenity with CT, Cancer Imaging, 2013.

F. Davnall, &. Connie, S. P. Yip, &. Gunnar-ljungqvist, &. et al., Assessment of tumor heterogeneity: an emerging imaging tool for clinical practice? Insights Imaging, 2012.

S. Mattonen, D. Palma, C. Haasbeek, S. Senan, and A. Ward, Early prediction of tumor recurrence based on CT texture changes after stereotactic ablative radiotherapy (SABR) for lung cancer, Medical Physics, vol.132, issue.suppl 6, 2014.
DOI : 10.1378/chest.06-2325

D. Campbell, CT Textural Analysis (CTTA) of Metastatic Treatment Resistant Pancreatic Adenocarcinoma (PDAC): Identifying Biomarkers for Genetic Instability and Overall Survival [Internet]. University of Arizona, 2016.

L. Marthey, A. Sa-cunha, J. Blanc, M. Gauthier, A. Cueff et al., FOLFIRINOX for Locally Advanced Pancreatic Adenocarcinoma: Results of an AGEO Multicenter Prospective Observational Cohort, Annals of Surgical Oncology, vol.17, issue.11, pp.295-301
DOI : 10.1245/s10434-010-1285-8

F. Petrelli, A. Coinu, K. Borgonovo, M. Cabiddu, M. Ghilardi et al., FOLFIRINOX-Based Neoadjuvant Therapy in Borderline Resectable or Unresectable Pancreatic Cancer, Pancreas, vol.44, issue.4, pp.515-536, 2015.
DOI : 10.1097/MPA.0000000000000314

M. Suker, B. Beumer, E. Sadot, L. Marthey, J. Faris et al., FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis, The Lancet Oncology, vol.17, issue.6, pp.801-811
DOI : 10.1016/S1470-2045(16)00172-8

N. Lopez, C. Prendergast, and A. Lowy, Borderline resectable pancreatic cancer: Definitions and management, World Journal of Gastroenterology, vol.20, issue.31, pp.10740-51, 2014.
DOI : 10.1371/journal.pmed.1000267

A. Mahipal, J. Frakes, S. Hoffe, and R. Kim, Management of borderline resectable pancreatic cancer, World J Gastrointest Oncol, vol.7, issue.10, pp.241-250, 2015.

C. Cassinotto, J. Cortade, G. Belleannée, B. Lapuyade, E. Terrebonne et al., An evaluation of the accuracy of CT when determining resectability of pancreatic head adenocarcinoma after neoadjuvant treatment, European Journal of Radiology, vol.82, issue.4, pp.589-93
DOI : 10.1016/j.ejrad.2012.12.002

R. Fischer, M. Breidert, T. Keck, F. Makowiec, C. Lohrmann et al., Early Recurrence of Pancreatic Cancer after Resection and During Adjuvant Chemotherapy, Saudi J Gastroenterol Off J Saudi Gastroenterol Assoc, vol.18, issue.2, pp.118-139, 2012.

A. Broeck, G. Sergeant, N. Ectors, W. Steenbergen, R. Aerts et al., Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma, European Journal of Surgical Oncology (EJSO), vol.35, issue.6, pp.600-604, 2009.
DOI : 10.1016/j.ejso.2008.12.006

D. Habermehl, I. Brecht, F. Bergmann, T. Welzel, S. Rieken et al., Chemoradiation in patients with isolated recurrent pancreatic cancer - therapeutical efficacy and probability of re-resection, Radiation Oncology, vol.8, issue.1, p.27, 2013.
DOI : 10.1186/1748-717X-8-27

S. Hishinuma, Y. Ogata, M. Tomikawa, I. Ozawa, K. Hirabayashi et al., Patterns of Recurrence After Curative Resection of Pancreatic Cancer, Based on Autopsy Findings, Journal of Gastrointestinal Surgery, vol.10, issue.4, pp.511-519, 2006.
DOI : 10.1016/j.gassur.2005.09.016

J. Delpero, J. Boher, A. Sauvanet, L. Treut, Y. Sa-cunha et al., Pancreatic Adenocarcinoma with Venous Involvement: Is Up-Front Synchronous Portal-Superior Mesenteric Vein Resection Still Justified? A Survey of the Association Fran??aise de Chirurgie, Annals of Surgical Oncology, vol.19, issue.suppl 3, pp.1874-83, 2015.
DOI : 10.1245/s10434-011-2110-8

M. Choti, E. Dixon, and D. Tyler, Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement by Callery et al., Annals of Surgical Oncology, vol.16, issue.7, 2009.
DOI : 10.1245/s10434-009-0411-y

M. Chuong, G. Springett, J. Freilich, C. Park, J. Weber et al., Stereotactic Body Radiation Therapy for Locally Advanced and Borderline Resectable Pancreatic Cancer Is Effective and Well Tolerated, International Journal of Radiation Oncology*Biology*Physics, vol.86, issue.3, pp.516-538, 2013.
DOI : 10.1016/j.ijrobp.2013.02.022

C. Pouypoudat, C. Périer, O. Saut, E. Buscail, C. Cassinotto et al., Analyse de textures dans les cancers pancréatiques avant et après radiochimiothérapie : nouveau paramètre prédictif? Soumission Abstract SFRO, 2017.